Jessica K R Boult Selected Research

CCI 103F

9/2013

Evaluation and immunohistochemical qualification of carbogen-induced ΔR₂ as a noninvasive imaging biomarker of improved tumor oxygenation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jessica K R Boult Research Topics

Disease

22	Neoplasms (Cancer) 01/2022 - 09/2010
6	Hypoxia (Hypoxemia) 04/2018 - 10/2012
4	Glioma (Gliomas) 11/2018 - 10/2012
3	Necrosis 04/2018 - 03/2012
2	Neuroblastoma 01/2020 - 01/2013
2	Breast Neoplasms (Breast Cancer) 11/2019 - 09/2017
2	Carcinoma (Carcinomatosis) 10/2018 - 04/2018
2	Prostatic Neoplasms (Prostate Cancer) 10/2018 - 10/2016
2	Fibrosis (Cirrhosis) 04/2018 - 01/2018
2	Glioblastoma (Glioblastoma Multiforme) 01/2018 - 09/2017
2	Brain Neoplasms (Brain Tumor) 01/2018 - 09/2017
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2018 - 01/2017
2	Prolactinoma (Prolactinomas) 09/2013 - 08/2013
1	Diffuse Intrinsic Pontine Glioma 01/2022
1	Squamous Cell Carcinoma of Head and Neck 01/2018
1	Contracture 01/2018
1	Cysts 01/2018
1	Hyperoxia 01/2018
1	Adenocarcinoma 11/2016
1	Colonic Neoplasms (Colon Cancer) 01/2016
1	Drug-Related Side Effects and Adverse Reactions 09/2015
1	Medulloblastoma 01/2015
1	Vascular Remodeling 10/2012
1	Colorectal Neoplasms (Colorectal Cancer) 07/2011

Drug/Important Bio-Agent (IBA)

15	Biomarkers (Surrogate Marker)IBA 01/2020 - 07/2011
6	ferumoxtran-10 (ultrasmall superparamagnetic iron oxide)IBA 01/2017 - 09/2010
5	carbogenIBA 10/2016 - 07/2011
4	pimonidazoleIBA 04/2018 - 10/2012
4	bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA 01/2018 - 07/2011
4	Oxygen (Dioxygen)IBA 01/2018 - 08/2013
4	Pharmaceutical PreparationsIBA 01/2018 - 01/2013
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2017 - 10/2012
3	CollagenIBA 11/2019 - 04/2015
3	cediranib (AZD2171)IBA 09/2017 - 10/2012
3	N-acetylcochinol-O-phosphateIBA 09/2015 - 03/2012
2	Gadolinium DTPA (Magnevist)FDA Link 01/2018 - 11/2016
1	dipinacoline glutamateIBA 01/2022
1	vistusertibIBA 01/2020
1	Aurora Kinase AIBA 01/2020
1	MLN 8237IBA 01/2020
1	Phosphotransferases (Kinase)IBA 01/2020
1	Collagenases (Collagenase)FDA Link 11/2019
1	Doxycycline (Periostat)FDA LinkGeneric 11/2018
1	ElementsIBA 11/2018
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 11/2018
1	MK 2206IBA 10/2018
1	Choline (Choline Chloride)IBA 10/2018
1	Methylnitrosourea (N-Methyl-N-nitrosourea)IBA 04/2018
1	C.I. direct red 80IBA 04/2018
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2018
1	Tyrosine Kinase InhibitorsIBA 01/2018
1	Contrast MediaIBA 01/2018
1	Immunoconjugates (Immunoconjugate)IBA 01/2018
1	ErbB Receptors (EGF Receptor)IBA 01/2018
1	Evans Blue (Blue, Evans)FDA Link 09/2017
1	Sunitinib (Sutent)FDA Link 01/2017
1	Hydralazine (Apresoline)FDA LinkGeneric 02/2016
1	Omalizumab (Xolair)FDA Link 01/2016
1	vanucizumabIBA 01/2016
1	Bevacizumab (Avastin)FDA Link 01/2016
1	Immunoglobulin E (IgE)IBA 01/2016
1	Biological ProductsIBA 01/2015
1	azomycinIBA 09/2013
1	CCI 103FIBA 09/2013
1	Hemoglobins (Hemoglobin)IBA 08/2013
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2013
1	Angiogenesis InhibitorsIBA 01/2013
1	2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidineIBA 01/2013
1	tandutinibIBA 01/2013
1	Eosine Yellowish-(YS) (Eosin)IBA 03/2012

Therapy/Procedure

14	Therapeutics 01/2022 - 10/2012
3	Aftercare (After-Treatment) 01/2016 - 10/2012
2	Intravenous Administration 10/2016 - 07/2011
1	Precision Medicine 01/2020
1	Mastectomy (Mammectomy) 01/2018
1	Radiotherapy 01/2018
1	Mammaplasty (Breast Reconstruction) 01/2018
1	Free Tissue Flaps 01/2018